Surviving Cutaneous Melanoma: A Clinical Review of Follow-up Practices, Surveillance, and Management of Recurrence

Surgical Clinics of North America

Volumn 94, Issue 5, 2014, Pages 989-1002

  Mrazek, Amy A ^a   Chao, Celia ^a  

^a University of Texas Medical Branch School of Medicine   (United States)

Author keywords

Management of recurrence; Melanoma survivorship; Surveillance and follow up; Survival prognosis

Indexed keywords

CANCER EPIDEMIOLOGY; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE FREE INTERVAL; DISTANT METASTASIS; FOLLOW UP; HUMAN; LYMPH NODE METASTASIS; MELANOMA; OVERALL SURVIVAL; PATIENT EDUCATION; PRACTICE GUIDELINE; REGIONAL METASTASIS; REVIEW; RISK FACTOR; SURVIVAL RATE; TUMOR INVASION; TUMOR VOLUME;

EID: 84907624135     PISSN: 00396109     EISSN: 15583171     Source Type: Journal    
DOI: 10.1016/j.suc.2014.07.003     Document Type: Review

References (55)

1. Howlader N, Noone AM, Krapcho M, etal. Surveillance, Epidemiology, and End Results (SEER) cancer statistics review, 1975-2010. Available at: . Accessed March 6, 2014. http://seer.cancer.gov/csr/1975_2010/.
2. MacKie R.M., Hauschild A., Eggermont A.M. Epidemiology of invasive cutaneous melanoma. Ann Oncol 2009, 20(Suppl 6):vi1-vi7.
3. Garbe C., Leiter U. Melanoma epidemiology and trends. Clin Dermatol 2009, 27:3-9.
4. Yang G.B., Barnholtz-Sloan J.S., Chen Y., et al. Risk and survival of cutaneous melanoma diagnosed subsequent to a previous cancer. Arch Dermatol 2011, 147:1395-1402.
5. Freedman D.M., Miller B.A., Tucker M.A. New malignancies following melanoma of the skin, eye melanoma, and non-melanoma eye cancer. New malignancies among cancer survivors: SEER cancer registries, 1973-2000 2006, 339-362. National Cancer Institute, Bethesda (MD). R.E. Curtis, D.M. Freedman, E. Ron (Eds.).
6. Balch C.M., Gershenwald J.E., Soong S.J., et al. Final version of 2009 AJCC melanoma staging and classification. JClin Oncol 2009, 27:6199-6206.
7. Breslow A. Thickness, cross-sectional areas and depth of invasion in the prognosis of cutaneous melanoma. Ann Surg 1970, 172:902-908.
8. Mervic L. Prognostic factors in patients with localized primary cutaneous melanoma. Acta Dermatovenerol Alp Pannonica Adriat 2012, 21:27-31.
9. Thompson J.F., Soong S.J., Balch C.M., et al. Prognostic significance of mitotic rate in localized primary cutaneous melanoma: an analysis of patients in the multi-institutional American Joint Committee on Cancer melanoma staging database. JClin Oncol 2011, 29:2199-2205.
10. Balch C.M., Soong S.J., Gershenwald J.E., et al. Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. JClin Oncol 2001, 19:3622-3634.
11. Fernandez-Flores A. Prognostic factors for melanoma progression and metastasis: from hematoxylin-eosin to genetics. Rom J Morphol Embryol 2012, 53:449-459.
12. Mervic L., Leiter U., Meier F., et al. Sex differences in survival of cutaneous melanoma are age dependent: an analysis of 7338 patients. Melanoma Res 2011, 21:244-252.
13. Chao C., Martin R.C., Ross M.I., et al. Correlation between prognostic factors and increasing age in melanoma. Ann Surg Oncol 2004, 11:259-264.
14. Garbe C., Buttner P., Bertz J., et al. Primary cutaneous melanoma. Prognostic classification of anatomic location. Cancer 1995, 75:2492-2498.
15. Collins K.K., Fields R.C., Baptiste D., et al. Racial differences in survival after surgical treatment for melanoma. Ann Surg Oncol 2011, 18:2925-2936.
16. Soong SJ, Ding S, Coit DG, etal. Individualized melanoma patient outcome prediction tools. Developed based on the American Joint Committee on Cancer Melanoma Database. Available at: . Accessed March 16, 2014. http://www.melanomaprognosis.org.
17. Callender G.G., Gershenwald J.E., Egger M.E., et al. Anovel and accurate computer model of melanoma prognosis for patients staged by sentinel lymph node biopsy: comparison with the American Joint Committee on Cancer model. JAm Coll Surg 2012, 214:608-619.
18. Garbe C., Paul A., Kohler-Spath H., et al. Prospective evaluation of a follow-up schedule in cutaneous melanoma patients: recommendations for an effective follow-up strategy. JClin Oncol 2003, 21:520-529.
19. Trotter S.C., Sroa N., Winkelmann R.R., et al. Aglobal review of melanoma follow-up guidelines. JClin Aesthet Dermatol 2013, 6:18-26.
20. McKenna D.B., Marioni J.C., Lee R.J., et al. Acomparison of dermatologists', surgeons' and general practitioners' surgical management of cutaneous melanoma. Br J Dermatol 2004, 151:636-644.
21. Epstein D.S., Lange J.R., Gruber S.B., et al. Is physician detection associated with thinner melanomas?. JAMA 1999, 281:640-643.
22. Francken A.B., Bastiaannet E., Hoekstra H.J. Follow-up in patients with localised primary cutaneous melanoma. Lancet Oncol 2005, 6:608-621.
23. Francken A.B., Shaw H.M., Accortt N.A., et al. Detection of first relapse in cutaneous melanoma patients: implications for the formulation of evidence-based follow-up guidelines. Ann Surg Oncol 2007, 14:1924-1933.
24. Salama A.K., de Rosa N., Scheri R.P., et al. Hazard-rate analysis and patterns of recurrence in early stage melanoma: moving towards a rationally designed surveillance strategy. PLoS One 2013, 8:e57665.
25. Cromwell K.D., Ross M.I., Xing Y., et al. Variability in melanoma post-treatment surveillance practices by country and physician specialty: a systematic review. Melanoma Res 2012, 22:376-385.
26. Coit DG, Thompson JA, Andtbacka R, etal. NCCN clinical practice guidelines in oncology (NCCN guidelines®) for melanoma (version 3.2014). Available at: . Accessed March 9, 2014. http://www.nccn.org/professionals/physician_gls/f_guidelines.asp.
27. Turner R.M., Bell K.J., Morton R.L., et al. Optimizing the frequency of follow-up visits for patients treated for localized primary cutaneous melanoma. JClin Oncol 2011, 29:4641-4646.
28. Fong Z.V., Tanabe K.K. Comparison of melanoma guidelines in the U.S.A., Canada, Europe, Australia and New Zealand: a critical appraisal and comprehensive review. Br J Dermatol 2014, 170:20-30.
29. Rychetnik L., McCaffery K., Morton R.L., et al. Follow-up of early stage melanoma: specialist clinician perspectives on the functions of follow-up and implications for extending follow-up intervals. JSurg Oncol 2013, 107:463-468.
30. Brown M.D. Office management of melanoma patients. Semin Cutan Med Surg 2010, 29:232-237.
31. Dunki-Jacobs E.M., Callender G.G., McMasters K.M. Current management of melanoma. Curr Probl Surg 2013, 50:351-382.
32. Mujumdar U.J., Hay J.L., Monroe-Hinds Y.C., et al. Sun protection and skin self-examination in melanoma survivors. Psychooncology 2009, 18:1106-1115.
33. Oliveria S.A., Chau D., Christos P.J., et al. Diagnostic accuracy of patients in performing skin self-examination and the impact of photography. Arch Dermatol 2004, 140:57-62.
34. Benvenuto-Andrade C., Oseitutu A., Agero A.L., et al. Cutaneous melanoma: surveillance of patients for recurrence and new primary melanomas. Dermatol Ther 2005, 18:423-435.
35. Lee T.K., Brazier A.S., Shoveller J.A., et al. Sun-related behavior after a diagnosis of cutaneous malignant melanoma. Melanoma Res 2007, 17:51-55.
36. Geller A.C., O'Riordan D.L., Oliveria S.A., et al. Overcoming obstacles to skin cancer examinations and prevention counseling for high-risk patients: results of a national survey of primary care physicians. JAm Board Fam Pract 2004, 17:416-423.
37. McLoone J.K., Watts K.J., Menzies S.W., et al. Melanoma survivors at high risk of developing new primary disease: a qualitative examination of the factors that contribute to patient satisfaction with clinical care. Psychooncology 2013, 22:1994-2000.
38. Kasparian N.A. Psychological stress and melanoma: are we meeting our patients' psychological needs?. Clin Dermatol 2013, 31:41-46.
39. Cella D.F., Tulsky D.S., Gray G., et al. The Functional Assessment of Cancer Therapy scale: development and validation of the general measure. JClin Oncol 1993, 11:570-579.
40. Sigurdardottir V., Bolund C., Brandberg Y., et al. The impact of generalized malignant melanoma on quality of life evaluated by the EORTC questionnaire technique. Qual Life Res 1993, 2:193-203.
41. Winstanley J.B., White E.G., Boyle F.M., et al. What are the pertinent quality-of-life issues for melanoma cancer patients? Aiming for the development of a new module to accompany the EORTC core questionnaire. Melanoma Res 2013, 23:167-174.
42. Tan J.D., Butow P.N., Boyle F.M., et al. Aqualitative assessment of psychosocial impact, coping and adjustment in high-risk melanoma patients and caregivers. Melanoma Res 2014, 24:252-260.
43. Vurnek M., Buljan M., Situm M. Psychological status and coping with illness in patients with malignant melanoma. Coll Antropol 2007, 31(Suppl 1):53-56.
44. Fawzy F.I., Fawzy N.W., Hyun C.S., et al. Malignant melanoma. Effects of an early structured psychiatric intervention, coping, and affective state on recurrence and survival 6 years later. Arch Gen Psychiatry 1993, 50:681-689.
45. Levine S.M., Shapiro R.L. Surgical treatment of malignant melanoma: practical guidelines. Dermatol Clin 2012, 30:487-501.
46. Squires M.H., Delman K.A. Current treatment of locoregional recurrence of melanoma. Curr Oncol Rep 2013, 15:465-472.
47. Romano E., Scordo M., Dusza S.W., et al. Site and timing of first relapse in stage III melanoma patients: implications for follow-up guidelines. JClin Oncol 2010, 28:3042-3047.
48. Morton D.L. Overview and update of the phase III Multicenter Selective Lymphadenectomy Trials (MSLT-I and MSLT-II) in melanoma. Clin Exp Metastasis 2012, 29:699-706.
49. Australian Cancer Network Melanoma Guidelines Revision Working Party. Clinical practice guidelines for the management of melanoma in Australia and New Zealand. Cancer Council Australia and Australian Cancer Network, Sydney and New Zealand Guidelines Group. Available at: . Accessed March 6, 2014. https://www.nhmrc.gov.au/guidelines/publications/cp111.
50. British Columbia Cancer Agency. Melanoma follow-up. Available at: . Accessed March 6, 2014. http://www.bccancer.bc.ca/HPI/CancerManagementGuidelines/Skin/Melanoma/ManagementPolicies/Follow-up.htm.
51. Alberta Cutaneous Tumor Team. Referral and follow-up surveillance of cutaneous melanoma. Available at: . Accessed March 6, 2014. http://www.albertahealthservices.ca/hp/if-hp-cancer-guide-cu001-followup-surveillance.pdf.
52. Dummer R., Hauschild A., Guggenheim M., et al. Cutaneous melanoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2012, 23(Suppl 7):vii86-vii91.
53. Pflugfelder A., Kochs C., Blum A., et al. S3-guideline "diagnosis, therapy and follow-up of melanoma"-short version. JDtsch Dermatol Ges 2013, 11:563-602.
54. Marsden J.R., Newton-Bishop J.A., Burrows L., et al. Revised UK guidelines for the management of cutaneous melanoma 2010. JPlast Reconstr Aesthet Surg 2010, 63:1401-1419.
55. Dummer R., Guggenheim M., Arnold A.W., et al. Updated Swiss guidelines for the treatment and follow-up of cutaneous melanoma. Swiss Med Wkly 2011, 141:w13320.